Lung cancer is one of the major causes of cancer related mortality worldwide. Brain
metastases (BM) complicate clinical evolution of non-small cell lung cancer (NSCLC) in …

Central nervous system (CNS) metastases are a common complication in patients with
epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) …

Introduction Brain metastases are one of the leading causes of death from non-small-cell
lung cancer (NSCLC). The use of epidermal growth factor receptor (EGFR) tyrosine kinase …

Brain metastases (BM) are a common occurrence in patients with non-small cell lung cancer
(NSCLC). Standard therapy options include whole brain radiotherapy and, in selected …

Brain metastases and/or leptomeningeal disease (LMD) with associated central nervous
system (CNS) metastases are known complications of advanced epidermal growth factor …

The incidence of brain metastasis (BM) is high in patients with non-small-cell lung cancer.
Available standard therapeutic options, such as whole-brain radiation therapy and systemic …

Simple Summary Targeted therapies have emerged as newer systemic options for certain
cancers. EGFR-directed Tyrosine Kinase Inhibitors (EGFR-TKIs), which have several …

Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)
mutations commonly present brain metastases (BM) at the time of NSCLC diagnosis or …

Patients with non-small-cell lung cancer (NSCLC), harboring Epidermal Growth Factor
Receptor (EGFR) mutations, are more susceptible to brain metastases (BM). Comparisons of …

Brain metastases are usual in non-small-cell lung cancer (NSCLC) with poor prognosis and
few available therapeutic options. This retrospective study aims to evaluate the efficacy of …